JP2009524422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009524422A5 JP2009524422A5 JP2008551872A JP2008551872A JP2009524422A5 JP 2009524422 A5 JP2009524422 A5 JP 2009524422A5 JP 2008551872 A JP2008551872 A JP 2008551872A JP 2008551872 A JP2008551872 A JP 2008551872A JP 2009524422 A5 JP2009524422 A5 JP 2009524422A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- binding
- terminal
- domain
- binding complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 34
- 229920001184 polypeptide Polymers 0.000 claims 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims 33
- 238000006471 dimerization reaction Methods 0.000 claims 9
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 239000012636 effector Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 230000003285 pharmacodynamic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0601513.5A GB0601513D0 (en) | 2006-01-25 | 2006-01-25 | Binding molecules 3 |
| PCT/GB2007/000258 WO2007085837A1 (en) | 2006-01-25 | 2007-01-25 | Binding molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009524422A JP2009524422A (ja) | 2009-07-02 |
| JP2009524422A5 true JP2009524422A5 (enExample) | 2010-03-11 |
Family
ID=36060850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551872A Pending JP2009524422A (ja) | 2006-01-25 | 2007-01-25 | 結合分子３ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090169548A1 (enExample) |
| EP (1) | EP1989229A1 (enExample) |
| JP (1) | JP2009524422A (enExample) |
| KR (1) | KR20080106201A (enExample) |
| CN (1) | CN101472946A (enExample) |
| AU (1) | AU2007209130A1 (enExample) |
| BR (1) | BRPI0706737A2 (enExample) |
| CA (1) | CA2637945A1 (enExample) |
| GB (1) | GB0601513D0 (enExample) |
| RU (1) | RU2008134519A (enExample) |
| TW (1) | TW200808824A (enExample) |
| WO (1) | WO2007085837A1 (enExample) |
| ZA (1) | ZA200806492B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2667729T3 (es) | 2007-09-26 | 2018-05-14 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
| WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| DK2417156T3 (en) | 2009-04-07 | 2015-03-02 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| EP3028565B1 (en) | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
| CA2781519A1 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| CA2807278A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann - La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| JP5764677B2 (ja) | 2011-02-28 | 2015-08-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗原結合タンパク質 |
| CN103403025B (zh) | 2011-02-28 | 2016-10-12 | 弗·哈夫曼-拉罗切有限公司 | 单价抗原结合蛋白 |
| EP2757875B2 (en) | 2011-09-19 | 2023-03-22 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| AU2012316859A1 (en) * | 2011-09-29 | 2014-04-17 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| SG11201401422VA (en) * | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| EP2802356A1 (en) | 2012-01-13 | 2014-11-19 | Apo-T B.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
| GB2502127A (en) * | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| CN102851338A (zh) * | 2012-07-25 | 2013-01-02 | 苏州康宁杰瑞生物科技有限公司 | 利用电荷排斥作用制备同二聚体蛋白混合物的方法 |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| GB2518221A (en) * | 2013-09-16 | 2015-03-18 | Sergej Michailovic Kiprijanov | Tetravalent antigen-binding protein molecule |
| WO2015049517A2 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
| RU2016115866A (ru) | 2013-10-11 | 2017-11-16 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| US10358497B2 (en) | 2015-09-29 | 2019-07-23 | Amgen Inc. | Methods of treating cardiovascular disease with an ASGR inhibitor |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| JP2020537506A (ja) | 2017-10-04 | 2020-12-24 | アムジエン・インコーポレーテツド | トランスサイレチン免疫グロブリン融合物 |
| GB2576914A (en) * | 2018-09-06 | 2020-03-11 | Kymab Ltd | Antigen-binding molecules comprising unpaired variable domains produced in mammals |
| MX2021014931A (es) | 2019-06-07 | 2022-01-24 | Amgen Inc | Construcciones de union biespecificas con enlazadores selectivamente escindibles. |
| CN113461824A (zh) * | 2020-03-31 | 2021-10-01 | 普米斯生物技术(珠海)有限公司 | 一种构建多特异性抗体的平台 |
| US20230203198A1 (en) | 2020-06-04 | 2023-06-29 | Amgen Inc. | Bispecific binding constructs |
| CA3203468A1 (en) | 2020-12-03 | 2022-06-09 | Amgen Inc. | Immunoglobuline constructs with multiple binding domains |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ121599A3 (cs) * | 1998-04-09 | 1999-10-13 | Aventis Pharma Deutschland Gmbh | Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu |
| AU2001270609A1 (en) * | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| EP1558647B1 (en) * | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| WO2006008548A2 (en) * | 2004-07-22 | 2006-01-26 | Erasmus University Medical Centre Rotterdam | Binding molecules |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
-
2006
- 2006-01-25 GB GBGB0601513.5A patent/GB0601513D0/en not_active Ceased
-
2007
- 2007-01-25 US US12/161,986 patent/US20090169548A1/en not_active Abandoned
- 2007-01-25 RU RU2008134519/13A patent/RU2008134519A/ru not_active Application Discontinuation
- 2007-01-25 KR KR1020087020710A patent/KR20080106201A/ko not_active Withdrawn
- 2007-01-25 TW TW096102902A patent/TW200808824A/zh unknown
- 2007-01-25 CN CNA200780010769XA patent/CN101472946A/zh active Pending
- 2007-01-25 ZA ZA200806492A patent/ZA200806492B/xx unknown
- 2007-01-25 EP EP07705029A patent/EP1989229A1/en not_active Withdrawn
- 2007-01-25 JP JP2008551872A patent/JP2009524422A/ja active Pending
- 2007-01-25 WO PCT/GB2007/000258 patent/WO2007085837A1/en not_active Ceased
- 2007-01-25 CA CA002637945A patent/CA2637945A1/en not_active Abandoned
- 2007-01-25 AU AU2007209130A patent/AU2007209130A1/en not_active Abandoned
- 2007-01-25 BR BRPI0706737-2A patent/BRPI0706737A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009524422A5 (enExample) | ||
| JP7703486B2 (ja) | Ｔｃｒライブラリ | |
| JP7244567B2 (ja) | 新規結合ドメイン含有ポリペプチドおよびその使用 | |
| JP2020517294A5 (enExample) | ||
| Lu et al. | Di-diabody: a novel tetravalent bispecific antibody molecule by design | |
| Jendeberg et al. | Engineering of Fc1 and Fc3 from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A | |
| JP2014158485A5 (enExample) | ||
| JP5150488B2 (ja) | Ｆｃ領域含有タンパク質を精製する方法 | |
| JP2019519227A5 (enExample) | ||
| IL275743A (en) | New bispecific format suitable for use in high-through-put screening | |
| JP2019068822A5 (enExample) | ||
| JP2021042257A5 (enExample) | ||
| JP2011526794A5 (enExample) | ||
| JP2020515518A5 (enExample) | ||
| CA2468583A1 (en) | Self-assembling multimeric binding complexes derived from ab5 toxin family members | |
| JP2020517287A5 (enExample) | ||
| JP2022171730A5 (enExample) | ||
| RU2015129640A (ru) | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 | |
| JP2019500862A5 (enExample) | ||
| JP2018537421A5 (enExample) | ||
| WO2003057829A3 (en) | Methods of generating multispecific, multivalent agents from vh and vl domains | |
| JP2010502183A5 (enExample) | ||
| JP2011526792A5 (enExample) | ||
| JP2005506064A5 (enExample) | ||
| JP2013163673A5 (enExample) |